IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

Condition:   NSCLC Interventions:   Biological: IO102;   Biological: pembrolizumab (Keytruda);   Drug: Carboplatin (Carboplatin Kabi);   Drug: Pemetrexed (Pemetrexed Alvogen) Sponsors:   IO Biotech;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials